Literature DB >> 16469946

Cardiac and vascular hypertrophy in Fabry disease: evidence for a new mechanism independent of blood pressure and glycosphingolipid deposition.

Frédéric Barbey1, Noureddine Brakch, Ales Linhart, Nathalie Rosenblatt-Velin, Xavier Jeanrenaud, Salah Qanadli, Beat Steinmann, Michel Burnier, Tomas Palecek, Jan Bultas, Daniel Hayoz.   

Abstract

OBJECTIVE: Fabry disease is an X-linked disorder resulting from alpha-galactosidase A deficiency. The cardiovascular findings include left ventricular hypertrophy (LVH) and increased intima-media thickness of the common carotid artery (CCA IMT). The current study examined the possible correlation between these parameters. To corroborate these clinical findings in vitro, plasma from Fabry patients was tested for possible proliferative effect on rat vascular smooth muscle cells (vascular smooth muscle cell [VSMC]) and mouse neonatal cardiomyocytes. METHODS AND
RESULTS: Thirty male and 38 female patients were enrolled. LVH was found in 60% of men and 39% of women. Increased CCA IMT was equally present in males and females. There was a strong positive correlation between LV mass and CCA IMT (r2=0.27; P<0.0001). VSMC and neonatal cardiomyocyte proliferative response in vitro correlated with CCA IMT (r2=0.39; P<0.0004) and LV mass index (r2=0.19; P=0.028), respectively.
CONCLUSIONS: LVH and CCA IMT occur concomitantly in Fabry suggesting common pathogenesis. The underlying cause may be a circulating growth-promoting factor whose presence has been confirmed in vitro.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16469946     DOI: 10.1161/01.ATV.0000209649.60409.38

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  25 in total

1.  Variations in the GLA gene correlate with globotriaosylceramide and globotriaosylsphingosine analog levels in urine and plasma.

Authors:  Susana Ferreira; Christiane Auray-Blais; Michel Boutin; Pamela Lavoie; José Pedro Nunes; Elisabete Martins; Scott Garman; João Paulo Oliveira
Journal:  Clin Chim Acta       Date:  2015-06-09       Impact factor: 3.786

2.  Lysosomal delivery of therapeutic enzymes in cell models of Fabry disease.

Authors:  D Marchesan; T M Cox; P B Deegan
Journal:  J Inherit Metab Dis       Date:  2012-03-24       Impact factor: 4.982

3.  Intravascular ultrasound assessment of coronary artery involvement in Fabry disease.

Authors:  T Kovarnik; G S Mintz; D Karetova; J Horak; J Bultas; R Skulec; H Skalicka; M Aschermann; M Elleder; A Linhart
Journal:  J Inherit Metab Dis       Date:  2008-11-08       Impact factor: 4.982

4.  Early cardiovascular remodelling in Fabry disease.

Authors:  Luca Costanzo; Sergio Buccheri; Piera Capranzano; Luigi Di Pino; Giuseppina Curatolo; Margherita Rodolico; Stefano Leggio; Anita Blundo; Corrado Tamburino; Ines Monte
Journal:  J Inherit Metab Dis       Date:  2013-04-25       Impact factor: 4.982

5.  Elevated globotriaosylsphingosine is a hallmark of Fabry disease.

Authors:  Johannes M Aerts; Johanna E Groener; Sijmen Kuiper; Wilma E Donker-Koopman; Anneke Strijland; Roelof Ottenhoff; Cindy van Roomen; Mina Mirzaian; Frits A Wijburg; Gabor E Linthorst; Anouk C Vedder; Saskia M Rombach; Josanne Cox-Brinkman; Pentti Somerharju; Rolf G Boot; Carla E Hollak; Roscoe O Brady; Ben J Poorthuis
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Genetic polymorphisms of vitamin D receptor (VDR) in Fabry disease.

Authors:  Michael Teitcher; Sarah Weinerman; Catharina Whybra; Michael Beck; Nir Sharon; Deborah Elstein; Gheona Altarescu
Journal:  Genetica       Date:  2008-02-16       Impact factor: 1.082

7.  Agalsidase alfa (Replagal) in the treatment of Anderson-Fabry disease.

Authors:  Gregory M Pastores
Journal:  Biologics       Date:  2007-09

Review 8.  Anderson-Fabry cardiomyopathy: prevalence, pathophysiology, diagnosis and treatment.

Authors:  Brendan N Putko; Kevin Wen; Richard B Thompson; John Mullen; Miriam Shanks; Haran Yogasundaram; Consolato Sergi; Gavin Y Oudit
Journal:  Heart Fail Rev       Date:  2015-03       Impact factor: 4.214

9.  Reduction of Plasma Globotriaosylsphingosine Levels After Switching from Agalsidase Alfa to Agalsidase Beta as Enzyme Replacement Therapy for Fabry Disease.

Authors:  Ozlem Goker-Alpan; Michael J Gambello; Gustavo H B Maegawa; Khan J Nedd; Daniel J Gruskin; Larry Blankstein; Neal J Weinreb
Journal:  JIMD Rep       Date:  2015-08-25

10.  Myofilament degradation and dysfunction of human cardiomyocytes in Fabry disease.

Authors:  Cristina Chimenti; Nazha Hamdani; Nicky M Boontje; Francesco DeCobelli; Antonio Esposito; Jean G F Bronzwaer; Ger J M Stienen; Matteo A Russo; Walter J Paulus; Andrea Frustaci; Jolanda van der Velden
Journal:  Am J Pathol       Date:  2008-05-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.